Saturday 17 October 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024. In the quarter to June 2026, revenue grew 64.4%, EPS grew 817.3%, free cash flow grew 400.7% and total debt rose 74.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
98.06
4.67
−4.55%
Follow BLLN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+5 more quarters Free account |
0.00 | 1,320.00 | 94.12 | 116.21 |
P/S ratio |
4.59 | 4.26 | 10.23 | 14.01 | |
P/FCF ratio |
0.00 | 82.68 | 137.37 | 167.83 | |
P/Operating CF |
113.67 | 120.39 | 234.99 | 609.40 | |
P/B ratio |
0.00 | 2.71 | 7.17 | 10.37 | |
Price to Tangible BV |
0.00 | 2.71 | 7.17 | 10.37 | |
EV/Sales |
4.03 | 2.82 | 8.97 | 12.86 | |
EV/EBITDA |
497.25 | 30.82 | 66.14 | 91.91 | |
EV/Operating CF |
185.22 | 35.00 | 84.99 | 112.67 | |
EV/FCF |
(246.78) | 54.78 | 120.43 | 154.04 | |
Quick Ratio |
5.63 | 11.21 | 10.47 | 11.19 | |
Current Ratio |
6.17 | 11.69 | 10.92 | 11.69 | |
Net Debt/EBITDA |
(11.10) | (32.98) | (21.48) | (51.40) | |
Debt/Assets |
16.93% | 9.10% | 12.88% | 12.50% | |
Debt/Equity |
(0.23) | 0.12 | 0.18 | 0.17 | |
Asset Turnover |
1.51 | 0.96 | 1.01 | 1.09 | |
Operating CF/Net income |
6.63 | 1.91 | 0.86 | 1.13 | |
Capex/Depreciation |
(0.72) | (0.52) | (1.50) | (1.19) | |
Interest Coverage |
481.65 | 3,444.00 | 1,783.40 | 687.88 | |
Research and Development Expense of Revenue |
15.51% | 14.84% | 13.56% | 15.82% | |
Selling, General and Administrative Expense of Revenue |
42.90% | 45.83% | 42.97% | 49.60% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.36% | 6.59% | 6.01% | 7.51% | |
Graham Net Nets |
(0.28) | 0.31 | 0.12 | 0.08 | |
Graham Number |
30.03 | 6.50 | 14.41 | 16.39 | |
Earnings Yield |
(1.60%) | 0.08% | 1.06% | 0.86% | |
Free Cash Flow Yield |
(0.36%) | 1.21% | 0.73% | 0.60% | |
Revenue per Share |
8.01 | 6.05 | 2.36 | 2.36 | |
Operating CF per Share |
0.96 | 0.68 | 0.34 | 0.20 | |
Capex per Share |
(0.20) | (0.10) | (0.10) | (0.09) | |
Free Cash Flow per Share |
0.75 | 0.58 | 0.24 | 0.11 | |
Cash per Share |
18.71 | 31.24 | 11.70 | 11.82 | |
Shareholders Equity per Share |
(22.96) | 30.24 | 11.01 | 11.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(22.96) | 30.24 | 11.01 | 11.57 | |
Free Cash Flow |
7.87 | 9.26 | 10.96 | 5.09 | |
Working Capital |
210.93 | 512.60 | 566.98 | 595.65 | |
Capital Expenditures |
(2.12) | (1.54) | (4.47) | (4.05) | |
Net Current Asset Value |
(315.32) | 408.01 | 429.03 | 458.49 | |
EV/EBIT |
0.00 | 53.72 | 87.88 | 118.01 | |
Capex to Sales |
0.03 | 0.02 | 0.04 | 0.04 | |
Price to Operating Income |
0.00 | 81.08 | 100.24 | 128.57 | |
| Other line items | |||||
Average Receivables |
— | — | — | 49.80 | |
Average Payables |
— | — | — | 8.25 | |
Average Inventory |
— | — | — | 14.93 | |
Average Assets |
163.76 | 316.33 | 350.36 | 364.85 | |
Average Common Equity |
— | — | — | 142.58 |
Columns are period end dates